Lutetium is the heaviest and rarest of the commercially produced stable lanthanides, and its commercial story is defined almost entirely by a single application: LYSO (lutetium yttrium orthosilicate) scintillator crystals, the enabling material for modern time-of-flight positron emission tomography (TOF-PET) medical imaging. Virtually every clinical PET/CT scanner manufactured in the past two decades uses LYSO or LSO as its detector crystal, exploiting lutetium's high density (7.1 g/cm³), excellent light yield, and fast scintillation timing. Lu₂O₃ is also used in petroleum refining catalysts, specialty glass, and laser host crystals, but these applications are secondary. The most rapidly growing Lu end use is Lu-177 radiopharmaceuticals — Lutathera (FDA-approved 2018) and Pluvicto (FDA-approved 2022) — which deliver targeted radiation therapy to neuroendocrine tumors and prostate cancer respectively, driving demand growth at a rate well above the underlying REE market.

Lutetium's supply chain is the most geographically concentrated of any commercially traded rare earth element. At a basket share of only ~0.05% of global REO production, world output is estimated at ~195 t Lu₂O₃ in 2024e from USGS-reported aggregate REO data — the smallest absolute production volume of any REE in regular commercial trade. The primary ore source is ion adsorption clay (IAC) deposits in southern China (Jiangxi, Fujian, Guangdong) and neighboring Southeast Asia (Myanmar, Thailand), which contain ~0.05–0.15% Lu₂O₃ — well above the global basket average and orders of magnitude above LREE-dominant bastnaesite deposits at Mountain Pass (CA) or Bayan Obo (CN). China controls approximately 95% of global Lu₂O₃ separation capacity, reflecting both its dominance in the IAC ore base and the specialized solvent extraction infrastructure required to separate the heaviest lanthanides. No significant ex-China Lu₂O₃ production at commercial scale exists. USGS MCS 2025 aggregate REO data underpins all production estimates; per-element tonnage is not disaggregated in public USGS reporting.

China's April 2025 imposition of direct export controls on lutetium — one of seven REEs explicitly named alongside Sm, Gd, Tb, Dy, Sc, and Y — represents the most acute supply risk materialization in the modern Lu market. Unlike the broader REE basket, where some non-Chinese production of La, Ce, and NdPr exists (US, Australia, Estonia), there is essentially no alternative supply chain for Lu₂O₃ at commercial scale. LYSO crystal growers outside China, Lu-177 radiopharmaceutical manufacturers, and medical device OEMs face structural dependence on Chinese export license approval for their primary feedstock. Burma's 28% production decline in 2024 further tightened the HREE supply picture. The combination of sub-200 t/year world production, single-supplier separation, direct export control targeting, and rapidly growing radiopharmaceutical demand makes lutetium one of the most supply-constrained materials in the critical minerals landscape.